Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Neurocrine Biosciences Inc (NBIX)  
$141.91 0.09 (0.06%) as of 4:30 Thu 5/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 93,430,000
Market Cap: 13.26(B)
Last Volume: 670,978 Avg Vol: 808,349
52 Week Range: $89.53 - $143.74
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  946
Guru Rank Value     : 0
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Neurocrine Biosciences is applying its capabilities into neuroscience to develop medicines for neurology, neuroendocrinology and neuropsychiatry-related disorders and diseases. Co.'s commercially available medicines include INGREZZA®, which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 mg, 60 mg and 80 mg capsules); and ONGENTYS®, which is a once-daily, peripherally acting Catechol-O-methyltransferase inhibitor utilized to prolong the duration of effect of levodopa, the primary treatment option for Parkinson's disease patients, during periods of the day where the effects of levodopa wear off and motor symptoms worsen.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 275,180 771,010 813,558 1,280,765
Total Sell Value $37,779,030 $101,803,598 $106,435,205 $158,397,673
Total People Sold 5 15 15 17
Total Sell Transactions 17 70 85 154
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 807
  Page 14 of 33  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bozigian Haig P. Chief Development Officer   •       –      –    2020-05-12 4 AS $114.94 $7,075,396 D/D (61,555) 148,633 -12%     
   Bozigian Haig P. Chief Development Officer   •       –      –    2020-05-12 4 OE $35.99 $3,884,054 D/D 61,555 166,690     -
   Grigoriadis Dimitri E. Chief Research Officer   •       –      –    2020-05-07 4 AS $105.44 $915,454 D/D (8,682) 104,741 3%     
   Abernethy Matt Chief Financial Officer   •       –      –    2020-05-07 4 AS $110.21 $1,653,134 D/D (15,000) 5,953 3%     
   Abernethy Matt Chief Financial Officer   •       –      –    2020-05-07 4 OE $73.60 $1,104,000 D/D 15,000 20,953     -
   Sherwin Stephen A Director   –       •      –    2020-04-28 4 AS $99.39 $1,757,966 D/D (17,687) 29,861 8%     
   Abernethy Matt Chief Financial Officer   •       –      –    2020-04-28 4 AS $102.49 $178,435 D/D (1,741) 5,953 8%     
   Roberts Eiry Chief Medical Officer   •       –      –    2020-04-24 4 AS $99.47 $192,376 D/D (1,934) 9,416 17%     
   Lloyd-Smith Malcolm Chief Regulatory Officer   •       –      –    2020-04-24 4 AS $99.45 $192,329 D/D (1,934) 24,941 17%     
   Gorman Kevin Charles Chief Executive Officer   •       •      –    2020-04-24 4 AS $99.45 $289,016 D/D (2,906) 434,971 17%     
   Abernethy Matt Chief Financial Officer   •       –      –    2020-04-24 4 AS $99.52 $192,467 D/D (1,934) 7,694 17%     
   Cooke Julie Chief Human Resources Officer   •       –      –    2020-04-24 4 AS $99.46 $192,364 D/D (1,934) 6,631 17%     
   Gano Kyle Chief Business Development Off   •       –      –    2020-04-24 4 AS $99.47 $192,377 D/D (1,934) 93,967 17%     
   Benevich Eric Chief Commercial Officer   •       –      –    2020-04-24 4 AS $99.45 $192,338 D/D (1,934) 13,344 17%     
   Grigoriadis Dimitri E. Chief Research Officer   •       –      –    2020-04-24 4 AS $99.41 $192,258 D/D (1,934) 113,423 17%     
   Bozigian Haig P. Chief Development Officer   •       –      –    2020-04-24 4 AS $99.46 $192,351 D/D (1,934) 148,633 17%     
   Lippoldt Darin Chief Legal Officer   •       –      –    2020-04-24 4 AS $99.49 $192,416 D/D (1,934) 26,021 17%     
   Benevich Eric Chief Commercial Officer   •       –      –    2020-04-15 4 AS $94.65 $817,018 D/D (8,632) 11,603 17%     
   Lloyd-Smith Malcolm Chief Regulatory Officer   •       –      –    2020-02-10 4 AS $104.56 $3,029,086 D/D (28,969) 23,200 24%     
   Lloyd-Smith Malcolm Chief Regulatory Officer   •       –      –    2020-02-10 4 OE $32.99 $1,728,147 D/D 28,969 39,127     -
   Benevich Eric Chief Commercial Officer   •       –      –    2020-02-07 4 AS $103.32 $209,747 D/D (2,030) 20,087 16%     
   Abernethy Matt Chief Financial Officer   •       –      –    2020-02-07 4 AS $103.35 $209,807 D/D (2,030) 5,701 16%     
   Cooke Julie Chief Human Resources Officer   •       –      –    2020-02-07 4 AS $103.26 $94,276 D/D (913) 4,643 16%     
   Lloyd-Smith Malcolm Chief Regulatory Officer   •       –      –    2020-02-07 4 AS $103.28 $104,827 D/D (1,015) 23,200 16%     
   Grigoriadis Dimitri E. Chief Research Officer   •       –      –    2020-02-07 4 AS $103.31 $125,833 D/D (1,218) 111,682 16%     
  807 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 14 of 33
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us